Adrafinil
Olmifon · CRL-40028
Last updated
At a glance
Overview
Adrafinil: The OTC Modafinil Prodrug#
Adrafinil is the original eugeroic developed by Lafon Laboratories in the 1970s, marketed as Olmifon in France until 2011, and now occupying a useful regulatory gap: modafinil sits on Schedule IV in the US, while adrafinil remains unscheduled and openly available through nootropic vendors. Hepatic hydrolysis converts it to modafinil, which does the actual work — meaning adrafinil functions as a slow-release modafinil prodrug with a ~45–90 minute onset lag and a rough 2:1 to 3:1 conversion ratio (600mg adrafinil ≈ 200mg modafinil equivalent).
The community runs it for what modafinil runs it for: clean, sustained focus without the catecholamine surge of amphetamines. Mechanistically it leans on partial DAT inhibition, α1-adrenergic activation, hypothalamic histamine release, and orexinergic activation — wakefulness signaling that mimics endogenous arousal rather than overriding it. Cutting-phase users appreciate the mild anorectic edge; deep-work users appreciate the 8–10 hour focus window from a single morning dose.
"Adrafinil is a prodrug that is metabolized in the liver to its active metabolite modafinil, resulting in increased wakefulness and vigilance with a favorable side effect profile." — Milgram et al., Neurobiology of Aging (2000)
The tradeoff is hepatic: that same liver conversion that makes adrafinil legal also produces transient ALT/AST/GGT elevations, which is why the community standard is 2–3 dosing days per week with intermittent cycles rather than daily use. The sections below cover documented adrafinil dosage ranges, the modafinil conversion math, stack pairings (caffeine + theanine, alpha-GPC, TUDCA support), hepatic monitoring cadence, and the protocol mistakes that turn a useful nootropic into a bloodwork problem.
How Adrafinil works
Hepatic Conversion to Modafinil#
Adrafinil itself is pharmacologically inert at the receptor level. The compound is a prodrug — hepatic amidases and esterases hydrolyze it into two metabolites: modafinil (the active species) and modafinil acid (inactive). This first-pass conversion is the source of both adrafinil's defining property (no scheduling) and its defining drawback (a hepatic processing tax that modafinil itself does not impose).
"Adrafinil is a prodrug that is metabolized in the liver to its active metabolite modafinil, resulting in increased wakefulness and vigilance with a favorable side effect profile." — Milgram, N. W., Callahan, H., Siwak, C. CNS Drug Reviews (2000)
The conversion ratio is roughly 2:1 to 3:1, meaning a 600 mg adrafinil dose yields somewhere in the neighborhood of 200 mg modafinil equivalent. The lag between parent compound and active metabolite is also why onset is 45–90 minutes slower than equivalent oral modafinil — the liver has to do its work before anything happens in the CNS.
Dopamine Transporter Inhibition#
Once modafinil crosses the blood-brain barrier, the primary wake-promoting node is partial inhibition of the dopamine transporter (DAT) in the striatum and nucleus accumbens. PET imaging in human subjects confirms occupancy at therapeutic doses with measurable increases in extracellular dopamine.
"Modafinil binds to the dopamine transporter, resulting in increased extracellular dopamine, particularly in the striatum and nucleus accumbens, which underlies its wake-promoting effects." — Volkow, N. D., Fowler, J. S., Logan, J., et al. JAMA (2009)
Critically, this is reuptake inhibition only — there is no monoamine-releasing component the way amphetamines have. That difference is the entire reason adrafinil/modafinil feels like "clean alertness" rather than catecholamine flood. The DAT occupancy is modest, the dopamine rise is gradual, and the subjective experience is focus rather than euphoria. The practical payoff for the user: long focus blocks (6–10 hours) without the comedown profile of stimulants.
α1-Adrenergic Activation#
The Lafon group's original characterization work demonstrated that adrafinil's wakefulness effect depends on α1-adrenergic signaling. Prazosin, an α1 antagonist, blocks the locomotor and arousal effects in animal models — meaning this pathway is not incidental but mechanistically required.
"The behavioral effects of modafinil, including increased locomotor activity, were blocked by prazosin, an α1-adrenergic antagonist, indicating a role of α1-adrenergic activation in its mechanism." — Duteil, J., Rambert, F. A., Pessonnier, J., et al. European Journal of Pharmacology (1990)
This α1 component is also why a mild rise in heart rate and blood pressure shows up at higher doses, and why users with uncontrolled hypertension or significant LVH are advised off the compound. For physique-focused users already running AAS-driven blood pressure elevation, the additive cardiovascular load is a real consideration — not a deal-breaker for a healthy lifter at 300–600 mg, but a reason to keep doses conservative on cycle.
Histaminergic and Orexinergic Tone#
Two further mechanisms separate modafinil from classical stimulants and explain the "wakefulness without arousal" subjective signature:
- Histamine release in the tuberomammillary nucleus — modafinil drives endogenous histaminergic wake signaling rather than substituting an exogenous stimulant for it. This is closer to mimicking natural circadian arousal than overriding it.
- Orexin/hypocretin neuron activation in the lateral hypothalamus — c-Fos mapping shows selective activation of the same neuronal population that fails in narcolepsy, which is why modafinil was originally developed and approved for that indication in the first place.
Layered on top, modafinil elevates cortical and thalamic glutamate while reducing GABA tone, producing the cognitive sharpening users actually pay for: faster working-memory turnover, longer sustained attention, and a clear mental "gear shift" rather than the jittery overdrive of high-dose caffeine.
Pharmacokinetic Tail and the Sleep Problem#
Adrafinil itself has a parent half-life of roughly 1 hour — irrelevant, because all the action is downstream. The modafinil metabolite is what dictates the actual duration of effect:
"Modafinil exhibits a terminal half-life of approximately 12–15 hours with the R-isomer showing slower clearance, accounting for prolonged pharmacologic effects after single oral administration." — Darwish, M., Kirby, M., Hellriegel, E. T., Robertson, P. Jr. Clinical Drug Investigation (2009)
This long tail is the single most important pharmacokinetic fact for practical use. A 600 mg adrafinil dose at 7 AM still has clinically meaningful modafinil concentrations at 9 PM. The protocol consequence is non-negotiable: dosing past late morning wrecks sleep architecture, and trying to compensate for a bad night with another dose the next morning is how users end up in a tolerance/sleep-debt spiral. The community standard of single morning administration on an empty stomach, with a hard cutoff ~10 hours before intended sleep, exists for this exact reason.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 300–300 mg | As needed | Documented entry-level range |
| Mid | 300–600 mg | As needed | Most commonly studied range |
| High | 900–1200 mg | As needed | Single morning dose on an empty stomach is the standard. Onset lags 45–90 minutes behind oral modafinil because of the hepatic conversion step. Avoid dosing within 10 hours of intended sleep — the modafinil tail will disrupt sleep architecture. Community standard is 2–3 dosing days per week maximum to limit hepatic load. |
Cycle length & outcomes
Documented cycle
1–2 weeks
Plateau after
4 wks
Cycle Length & Protocol Notes#
Adrafinil is not a "cycle" compound in the AAS sense — there is no receptor downregulation curve to manage and no HPTA suppression to recover from. The cycling logic is hepatic, not hormonal. The liver does the prodrug conversion, and chronic daily dosing produces the transient ALT/AST/GGT elevations that ultimately killed Olmifon as a prescription product in France. Every community protocol that has survived contact with bloodwork is built around pulsing usage to keep that hepatic load below the threshold where enzymes start drifting.
Adrafinil Dosage by Goal#
| Goal | Cycle Length | Per-Dose | Frequency |
|---|---|---|---|
| First exposure / tolerance check | Single dose | 300mg | One-off, AM |
| Long-form cognitive work blocks | 1–2 weeks | 600mg | 2–3 days/week, AM |
| Shift work / jet lag reset | Single dose | 300–600mg | Acute, not repeated within 48h |
| Cutting-phase focus + appetite | 1–2 weeks | 300–600mg | Training days only |
| Aggressive deep-work pushes | ≤1 week | 900–1200mg | Split AM + early-PM, occasional |
| Modafinil substitute | As needed | 600–900mg | ~2:1 to 3:1 adrafinil:modafinil equivalence |
The 600mg single morning dose is the operational center of gravity — it maps to roughly 200mg modafinil equivalent after hepatic conversion, which is the dose most published modafinil cognition work runs.
Onset & Timing#
The prodrug step costs roughly 45–90 minutes of onset latency compared to direct modafinil administration. Empty stomach in the morning is the default — food doesn't block absorption but it blunts the ramp.
"Modafinil exhibits a terminal half-life of approximately 12–15 hours with the R-isomer showing slower clearance, accounting for prolonged pharmacologic effects after single oral administration." — Darwish et al., Clinical Drug Investigation (2009)
That 12–15 hour metabolite tail is the operative number for sleep planning. A 7 AM dose still has meaningful modafinil concentration at 10 PM. Dosing past late morning is the single most common protocol error and the fastest route to a wrecked sleep cycle.
Loading & Tapering#
There is no loading phase. Adrafinil reaches its effective concentration on the first dose — the prodrug conversion is the only kinetic delay, not receptor saturation.
There is no tapering requirement either. The compound is not GABAergic, not opioidergic, and not associated with a withdrawal syndrome. Discontinuation is abrupt by default. Mild tolerance to the wake-promoting effect develops with daily use and resets within several days of washout, which is the mechanistic argument for the 2–3 days-per-week pattern even setting hepatic concerns aside.
Cycle Length Ceiling#
The community ceiling sits at ≤2 weeks of continuous use before a washout, and most experienced users never run it continuously — the dominant pattern is intermittent dosing on demand (Mon/Wed/Fri, or weekday clusters with weekends off) rather than block cycles. The original Olmifon prescribing window was open-ended for narcolepsy, but the patient population was elderly hypersomniacs under physician monitoring, not physique-focused users stacking hepatic loads from multiple directions.
For anyone running it more than once weekly, the protocol calls for built-in washout weeks every 4–6 weeks of intermittent use.
Bloodwork Cadence#
Hepatic monitoring is the non-negotiable piece:
- Baseline LFT panel (ALT, AST, GGT, ALP, total bilirubin) prior to initiating any sustained use pattern
- 6-week recheck for users dosing more than once per week
- Quarterly thereafter for ongoing intermittent users
- Immediate panel if any prodromal hepatic symptoms appear — RUQ discomfort, dark urine, scleral icterus, unusual fatigue
The community standard adjunct is TUDCA 250–500mg on dosing days, with NAC 600mg twice daily as the secondary option. Neither has direct RCT support in adrafinil users, but the mechanistic rationale is sound and the cost-benefit is favorable.
Stack Compatibility#
"Adrafinil is a prodrug that is metabolized in the liver to its active metabolite modafinil, resulting in increased wakefulness and vigilance with a favorable side effect profile." — Milgram et al., Neurobiology of Aging (2000)
The favorable profile holds in isolation. Stacking changes the math:
- Caffeine + L-theanine (200–300mg / 200mg) — universal pairing, smooths the ramp, no hepatic concern
- Alpha-GPC 300mg + oxiracetam 400mg or noopept 250mg — cholinergic support offsets the frontal headache some users get from dopamine-dominant monotherapy
- 17α-alkylated orals (Anavar, Superdrol, Anadrol, Dianabol, Winstrol) — avoid concurrent use. Hepatic loads compound.
- Injectable-only AAS cycles (testosterone, nandrolone, primobolan) — compatible, though intermittent adrafinil dosing remains the prudent default
- MAOIs — contraindicated
- Hormonal contraceptives — modafinil's CYP3A4 induction reduces plasma levels; barrier backup or a non-CYP3A4 method during use periods
Onset Expectations#
Subjective wakefulness and focus emerge 60–90 minutes post-dose and plateau through hours 3–8. The drop-off is gradual rather than a stimulant crash — a slow taper of alertness back to baseline over hours 9–12, with residual modafinil still detectable beyond that window. Cognitive benefits (focus, working memory, sustained attention) track the wakefulness curve closely; there is no separate "kick-in" phase to wait for and no front-loading benefit to multi-dose splits within a single day except at the upper 900–1200mg range.
For occasional, pulsed administration with baseline-normal liver function and respect for the timing window, adrafinil delivers most of what modafinil delivers, legally and over the counter. That trade — a hepatic conversion step in exchange for grey-market access — is the entire reason the compound still has a user base.
Risks & mistakes
Common (most users)#
- Frontal headache — the most frequently reported effect, typically dose-correlated. Hydration target ≥3L on dosing days and a cholinergic co-administration (alpha-GPC 300mg or CDP-choline 250mg) blunts it in most users. If the headache persists past the second dose, the protocol calls for a step down from 600mg to 300mg.
- Insomnia / disrupted sleep — driven by the 12–15 hour modafinil metabolite tail. Dosing strictly on waking and never within 10 hours of intended sleep solves this. A single 600mg dose at 7am is functionally a different compound from 600mg at noon.
- Appetite suppression — useful in a deficit, inconvenient in a bulk. Pre-portioned meals on dosing days, or a deliberate calorie target hit before the focus window opens.
- Dry mouth, mild nausea on empty stomach — adrafinil is conventionally administered fasted for absorption, but a small protein-fat snack 30 minutes in resolves the nausea without meaningfully blunting onset.
- Mild blood-pressure and heart-rate elevation — α1-adrenergic activation is part of the mechanism. Resting BP/HR readings on dosing days are reasonable for anyone running it more than occasionally.
"The behavioral effects of modafinil, including increased locomotor activity, were blocked by prazosin, an α1-adrenergic antagonist, indicating a role of α1-adrenergic activation in its mechanism." — Duteil et al., European Journal of Pharmacology (1990)
Uncommon (dose-dependent or individual)#
- Anxiety / overstimulation — more common at 900–1200mg or in users with high baseline dopaminergic tone. L-theanine 200mg with the dose smooths the edge; if it persists at 600mg the compound is the wrong fit and dose escalation is not the answer.
- Transient hepatic enzyme elevation (ALT, AST, GGT, ALP) — the dominant reason Olmifon was pulled in France in 2011 and the reason community protocols pulse rather than run daily. Baseline LFTs prior to initiating a cycle, with a repeat panel at 4–6 weeks for anyone dosing more than once weekly. Flagged values call for a full washout, not a dose reduction.
- Tachycardia / palpitations — uncommon at 300–600mg, more frequent at 900mg+. Back off to the floor dose or discontinue if resting HR climbs more than ~10bpm above baseline.
- Tolerance to the wakefulness effect — develops with daily use. The 2–3 days/week community standard exists specifically to prevent this; users who blow through it and chase the effect with higher doses end up with more hepatic load and less alertness.
- Reduced contraceptive efficacy — modafinil is a CYP3A4 inducer and lowers plasma levels of ethinyl estradiol-based contraception. Female users on hormonal contraception need a non-CYP3A4 method or barrier backup during dosing weeks.
"Modafinil exhibits a terminal half-life of approximately 12–15 hours with the R-isomer showing slower clearance, accounting for prolonged pharmacologic effects after single oral administration." — Darwish et al., Clinical Drug Investigation (2009)
Rare but serious#
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, DRESS — documented in the modafinil prescribing information. Incidence is low but the severity is non-negotiable. Any new rash, mucosal involvement, fever, or facial swelling on adrafinil = discontinue immediately and seek medical evaluation. This is the one warning that does not get rationalised away.
- Clinically significant hepatotoxicity — beyond the transient enzyme bumps, frank hepatic injury has been reported with chronic high-dose Olmifon use. Warning signs: RUQ pain, jaundice, dark urine, persistent fatigue out of proportion to training load. Stop and pull a full hepatic panel.
- Severe hypertensive response — rare but reported, particularly in users with undiagnosed baseline hypertension or stacked with other sympathomimetics.
- Psychiatric reactions — mania, psychosis, and severe anxiety have appeared in modafinil case reports, almost always in users with predisposing history. Discontinue if mood becomes labile.
"Serious rash, including Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), has been reported in association with modafinil use." — FDA Modafinil Prescribing Information (2015)
Hard contraindications#
- Hepatic impairment — any baseline elevation in LFTs, fatty liver disease, hepatitis, or recent hepatic insult disqualifies use. The conversion step happens in the liver and the hepatic load is real.
- Concurrent 17α-alkylated oral AAS — Anadrol, Superdrol, Dianabol, Anavar, Winstrol, M1T. The hepatic load stacks and the combination is reckless. Adrafinil during an injectable-only cycle (test, nandrolone, primo) is a different conversation.
- MAOI co-administration — contraindicated. The catecholaminergic interaction is dangerous.
- Uncontrolled hypertension, recent MI, left ventricular hypertrophy, significant arrhythmia history — α1-adrenergic activation plus dopaminergic load is the wrong stimulus profile for a compromised cardiovascular system.
- Prior dermatologic reaction to modafinil or armodafinil — any history of SJS, TEN, DRESS, or unexplained drug rash on modafinil is a permanent contraindication to adrafinil. The active metabolite is identical.
- Heavy alcohol use — compounds the hepatic load and the modafinil-alcohol interaction is unpredictable.
Gender and PCT considerations#
Adrafinil is non-hormonal — dosing is identical for male and female users and no PCT is required. The one female-specific note is the CYP3A4 contraceptive interaction above: hormonal contraception efficacy drops during dosing weeks, and barrier backup or a non-CYP3A4 method is the documented workaround. Pregnancy and lactation are contraindications by default — no controlled human data exists and modafinil itself carries a pregnancy-category warning. For male users planning conception, no fertility signal has been reported in the literature, but the standard "minimise hepatic load during a TRT cruise or conception window" logic applies.
FAQ — Adrafinil
Research & citations
5 studies cited on this page.
Conclusion
Adrafinil sits in a unique spot as an accessible, effective eugeroic with a rapid onset after hepatic conversion to modafinil. Its real value is in enabling high-focus, wakeful cognitive work for those without prescription modafinil access, with managed risk via intermittent pulsed use.
Key takeaways:
- Standard protocol: 300–600 mg oral, single morning dose, onset ~60–90 minutes
- Cycle pattern: 2–3 days/week or ≤2 weeks continuous to limit hepatic load
- Active window: 8–12 hours of clean wakefulness and enhanced focus; avoid dosing within 10 hours of intended sleep
- Stacking: caffeine + L-theanine is a community mainstay; add cholinergics (alpha-GPC, racetams) for long-form work
- Hepatic monitoring: baseline + periodic LFTs are best practice; avoidance with oral AAS or pre-existing liver issues is non-negotiable
- Skin reactions (SJS/DRESS): rare but serious; any rash = stop immediately (FDA Modafinil Label)
For researchers prioritizing wakefulness, cognitive drive, and appetite suppression with an evidence-based protocol, adrafinil remains a top nootropic—provided the cycle structure and liver care are respected.